Exact Mass: 556.2361952
Exact Mass Matches: 556.2361952
Found 500 metabolites which its exact mass value is equals to given mass value 556.2361952
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
RD4-2174
Ingenol 3,20-dibenzoate is a benzoate ester. Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate induces selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induces morphologically typical apoptosis through de novo synthesis of macromolecules. Ingenol 3,20-dibenzoate increases the IFN-γ production and degranulation by NK cells, especially when NK cells are stimulated by NSCLC cells[1][2]. Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate induces selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induces morphologically typical apoptosis through de novo synthesis of macromolecules. Ingenol 3,20-dibenzoate increases the IFN-γ production and degranulation by NK cells, especially when NK cells are stimulated by NSCLC cells[1][2].
2-O-[6-O-Octanoyl-alpha-D-glucopyranosyl-(1->6)-alpha-D-glucopyranosyl]-D-glycerate
Sjg-136
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
Glaucarubolone 15-O-beta-D-glucopyranoside
Glaucarubolone 15-O-beta-D-glucopyranoside is found in fats and oils. Glaucarubolone 15-O-beta-D-glucopyranoside is a constituent of Simarouba glauca (aceituno) Constituent of Simarouba glauca (aceituno). Glaucarubolone 15-O-beta-D-glucopyranoside is found in fats and oils.
Dipiperamide C
C33H36N2O6 (556.2573236000001)
Dipiperamide C is found in herbs and spices. Dipiperamide C is an alkaloid from white pepper, Piper nigrum. Alkaloid from white pepper, Piper nigrum. Dipiperamide C is found in herbs and spices.
N-[4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
Fluticasone propimonate
Pexmetinib
O-Desmethyl Midostaurin
PA(2:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))
PA(2:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Resolvin D5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/2:0)
PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/2:0), in particular, consists of one chain of one Resolvin D5 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))
PA(2:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Protectin DX at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/2:0)
PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/2:0), in particular, consists of one chain of one Protectin DX at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Lariciresinol-sesquilignan
Lariciresinol-sesquilignan is a member of the class of compounds known as 7,9-epoxylignans. 7,9-epoxylignans are lignans that contain the 7,9-epoxylignan skeleton, which consists of a tetrahydrofuran that carries a phenyl group, a methyl group, and a benzyl group at the 2-, 3-, 4-position, respectively. Lariciresinol-sesquilignan is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Lariciresinol-sesquilignan can be found in sesame, which makes lariciresinol-sesquilignan a potential biomarker for the consumption of this food product.
Iryantherin G
Interiotherin C
A lignan with a dibenzocyclooctadiene skeleton attached to a fatty acid ester and acetate side chains. It is isolated from Kadsura ananosma and has been shown to exhibit neuroprotective activity.
Iryantherin H
SSR 69071
CONFIDENCE standard compound; INTERNAL_ID 510; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8076; ORIGINAL_PRECURSOR_SCAN_NO 8073 CONFIDENCE standard compound; INTERNAL_ID 510; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8117; ORIGINAL_PRECURSOR_SCAN_NO 8114 CONFIDENCE standard compound; INTERNAL_ID 510; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8117; ORIGINAL_PRECURSOR_SCAN_NO 8115 CONFIDENCE standard compound; INTERNAL_ID 510; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8152; ORIGINAL_PRECURSOR_SCAN_NO 8150 CONFIDENCE standard compound; INTERNAL_ID 510; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8162; ORIGINAL_PRECURSOR_SCAN_NO 8160 CONFIDENCE standard compound; INTERNAL_ID 510; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8177; ORIGINAL_PRECURSOR_SCAN_NO 8174
23-(R)-photogedunin acetate|alpha-photogedunin acetate|beta-photogedunin acetate
punaglandin 1
ilexin C|methyl (4E)-3-{[(2R,3R,4R,4S)-3,4-dihydro-6-hydroxy-4-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-7-methoxyspiro[1,3-dioxolane-4,2(1H)-naphthalen]-2-yl]methyl}-4-formylhex-4-enoate
3a,14-dihydroxy-9,13a,15a-trimethyl-1-(2-oxo-2h-pyran-5-yl)hexadecahydro-4ah,7ah-11,12a-epoxycyclopenta[7,8]oxireno[8a,9]phenanthro[2,3-b]pyrano[3,2-e][1,4]dioxin-15(1h)-one
11beta,12alpha-diacetoxy-1-deoxo-14beta,15beta-epoxy-3beta-hydroxy-2-oxoneotecleanin|11??,12??-Diacetoxy-1-deoxo-14??,15??-epoxy-3??-hydroxy-2-oxo-neotecleanin
6,9-Dihydroxymegastigm-7-en-3-one 9-O-beta-D-glucopyranoside tetraacetate
threo-guaiacylglycerol-beta-O-4-lariciresinol ether
5alpha,13alpha,15beta-trihydroxy-16beta-methoxyl-1alpha,6alpha,7beta-triacetoxy-12-oxocassane-14,16-epoxy|neocaesalpin AE
methyl-2-hydroxy-3beta-isobutyroxy-1-oxomeliac-8(30)-enate
Asp Glu Phe Phe
Asp Phe Glu Phe
Asp Phe Phe Glu
Asp Phe Ile Tyr
Asp Phe Leu Tyr
Asp Phe Tyr Ile
Asp Phe Tyr Leu
Asp Ile Phe Tyr
Asp Ile Tyr Phe
Asp Leu Phe Tyr
Asp Leu Tyr Phe
Asp Pro Tyr Tyr
Asp Tyr Phe Ile
Asp Tyr Phe Leu
Asp Tyr Ile Phe
Asp Tyr Leu Phe
Asp Tyr Pro Tyr
Asp Tyr Tyr Pro
Glu Asp Phe Phe
Glu Phe Asp Phe
Glu Phe Phe Asp
Glu Phe Met Met
Glu Phe Val Tyr
Glu Phe Tyr Val
Glu Met Phe Met
Glu Met Met Phe
Glu Val Phe Tyr
Glu Val Tyr Phe
Glu Tyr Phe Val
Glu Tyr Val Phe
Phe Asp Glu Phe
Phe Asp Phe Glu
Phe Asp Ile Tyr
Phe Asp Leu Tyr
Phe Asp Tyr Ile
Phe Asp Tyr Leu
Phe Glu Asp Phe
Phe Glu Phe Asp
Phe Glu Met Met
Phe Glu Val Tyr
Phe Glu Tyr Val
Phe Phe Asp Glu
Phe Phe Glu Asp
Phe Phe Phe Pro
Phe Phe Ile Met
Phe Phe Leu Met
Phe Phe Met Ile
Phe Phe Met Leu
Phe Phe Pro Phe
Phe Ile Asp Tyr
Phe Ile Phe Met
Phe Ile Met Phe
Phe Ile Tyr Asp
Phe Leu Asp Tyr
Phe Leu Phe Met
Phe Leu Met Phe
Phe Leu Tyr Asp
Phe Met Glu Met
Phe Met Phe Ile
Phe Met Phe Leu
Phe Met Ile Phe
Phe Met Leu Phe
Phe Met Met Glu
Phe Met Pro Tyr
Phe Met Tyr Pro
Phe Asn Asn Tyr
Phe Asn Tyr Asn
Phe Pro Phe Phe
Phe Pro Met Tyr
Phe Pro Tyr Met
Phe Val Glu Tyr
Phe Val Tyr Glu
Phe Tyr Asp Ile
Phe Tyr Asp Leu
Phe Tyr Glu Val
Phe Tyr Ile Asp
Phe Tyr Leu Asp
Phe Tyr Met Pro
Phe Tyr Asn Asn
Phe Tyr Pro Met
Phe Tyr Val Glu
His His Thr Tyr
C25H32N8O7 (556.2393841999999)
His His Tyr Thr
C25H32N8O7 (556.2393841999999)
His Lys Ser Trp
His Lys Trp Ser
His Met Asn Arg
C21H36N10O6S (556.2539876000001)
His Met Arg Asn
C21H36N10O6S (556.2539876000001)
His Asn Met Arg
C21H36N10O6S (556.2539876000001)
His Asn Arg Met
C21H36N10O6S (556.2539876000001)
His Asn Thr Trp
C25H32N8O7 (556.2393841999999)
His Asn Trp Thr
C25H32N8O7 (556.2393841999999)
His Gln Ser Trp
C25H32N8O7 (556.2393841999999)
His Gln Trp Ser
C25H32N8O7 (556.2393841999999)
His Arg Met Asn
C21H36N10O6S (556.2539876000001)
His Arg Asn Met
C21H36N10O6S (556.2539876000001)
His Ser Lys Trp
His Ser Gln Trp
C25H32N8O7 (556.2393841999999)
His Ser Trp Lys
His Ser Trp Gln
C25H32N8O7 (556.2393841999999)
His Thr His Tyr
C25H32N8O7 (556.2393841999999)
His Thr Asn Trp
C25H32N8O7 (556.2393841999999)
His Thr Trp Asn
C25H32N8O7 (556.2393841999999)
His Thr Tyr His
C25H32N8O7 (556.2393841999999)
His Trp Lys Ser
His Trp Asn Thr
C25H32N8O7 (556.2393841999999)
His Trp Gln Ser
C25H32N8O7 (556.2393841999999)
His Trp Ser Lys
His Trp Ser Gln
C25H32N8O7 (556.2393841999999)
His Trp Thr Asn
C25H32N8O7 (556.2393841999999)
His Tyr His Thr
C25H32N8O7 (556.2393841999999)
His Tyr Thr His
C25H32N8O7 (556.2393841999999)
Ile Asp Phe Tyr
Ile Asp Tyr Phe
Ile Phe Asp Tyr
Ile Phe Phe Met
Ile Phe Met Phe
Ile Phe Tyr Asp
Ile Met Phe Phe
Ile Met Met Tyr
Ile Met Tyr Met
Ile Tyr Asp Phe
Ile Tyr Phe Asp
Ile Tyr Met Met
Lys His Ser Trp
Lys His Trp Ser
Lys Ser His Trp
Lys Ser Trp His
Lys Trp His Ser
Lys Trp Ser His
Leu Asp Phe Tyr
Leu Asp Tyr Phe
Leu Phe Asp Tyr
Leu Phe Phe Met
Leu Phe Met Phe
Leu Phe Tyr Asp
Leu Met Phe Phe
Leu Met Met Tyr
Leu Met Tyr Met
Leu Tyr Asp Phe
Leu Tyr Phe Asp
Leu Tyr Met Met
Met Glu Phe Met
Met Glu Met Phe
Met Phe Glu Met
Met Phe Phe Ile
Met Phe Phe Leu
Met Phe Ile Phe
Met Phe Leu Phe
Met Phe Met Glu
Met Phe Pro Tyr
Met Phe Tyr Pro
Met His Asn Arg
C21H36N10O6S (556.2539876000001)
Met His Arg Asn
C21H36N10O6S (556.2539876000001)
Met Ile Phe Phe
Met Ile Met Tyr
Met Ile Tyr Met
Met Leu Phe Phe
Met Leu Met Tyr
Met Leu Tyr Met
Met Met Glu Phe
Met Met Phe Glu
Met Met Ile Tyr
Met Met Leu Tyr
Met Met Tyr Ile
Met Met Tyr Leu
Met Asn His Arg
C21H36N10O6S (556.2539876000001)
Met Asn Arg His
C21H36N10O6S (556.2539876000001)
Met Pro Phe Tyr
Met Pro Tyr Phe
Met Arg His Asn
C21H36N10O6S (556.2539876000001)
Met Arg Asn His
C21H36N10O6S (556.2539876000001)
Met Tyr Phe Pro
Met Tyr Ile Met
Met Tyr Leu Met
Met Tyr Met Ile
Met Tyr Met Leu
Met Tyr Pro Phe
Asn Phe Asn Tyr
Asn Phe Tyr Asn
Asn His Met Arg
C21H36N10O6S (556.2539876000001)
Asn His Arg Met
C21H36N10O6S (556.2539876000001)
Asn His Thr Trp
C25H32N8O7 (556.2393841999999)
Asn His Trp Thr
C25H32N8O7 (556.2393841999999)
Asn Met His Arg
C21H36N10O6S (556.2539876000001)
Asn Met Arg His
C21H36N10O6S (556.2539876000001)
Asn Asn Phe Tyr
Asn Asn Tyr Phe
Asn Arg His Met
C21H36N10O6S (556.2539876000001)
Asn Arg Met His
C21H36N10O6S (556.2539876000001)
Asn Thr His Trp
C25H32N8O7 (556.2393841999999)
Asn Thr Trp His
C25H32N8O7 (556.2393841999999)
Asn Trp His Thr
C25H32N8O7 (556.2393841999999)
Asn Trp Thr His
C25H32N8O7 (556.2393841999999)
Asn Tyr Phe Asn
Asn Tyr Asn Phe
Pro Asp Tyr Tyr
Pro Phe Phe Phe
Pro Phe Met Tyr
Pro Phe Tyr Met
Pro Met Phe Tyr
Pro Met Tyr Phe
Pro Tyr Asp Tyr
Pro Tyr Phe Met
Pro Tyr Met Phe
Pro Tyr Tyr Asp
Gln His Ser Trp
C25H32N8O7 (556.2393841999999)
Gln His Trp Ser
C25H32N8O7 (556.2393841999999)
Gln Ser His Trp
C25H32N8O7 (556.2393841999999)
Gln Ser Trp His
C25H32N8O7 (556.2393841999999)
Gln Trp His Ser
C25H32N8O7 (556.2393841999999)
Gln Trp Ser His
C25H32N8O7 (556.2393841999999)
Arg His Met Asn
C21H36N10O6S (556.2539876000001)
Arg His Asn Met
C21H36N10O6S (556.2539876000001)
Arg Met His Asn
C21H36N10O6S (556.2539876000001)
Arg Met Asn His
C21H36N10O6S (556.2539876000001)
Arg Asn His Met
C21H36N10O6S (556.2539876000001)
Arg Asn Met His
C21H36N10O6S (556.2539876000001)
Ser His Lys Trp
Ser His Gln Trp
C25H32N8O7 (556.2393841999999)
Ser His Trp Lys
Ser His Trp Gln
C25H32N8O7 (556.2393841999999)
Ser Lys His Trp
Ser Lys Trp His
Ser Gln His Trp
C25H32N8O7 (556.2393841999999)
Ser Gln Trp His
C25H32N8O7 (556.2393841999999)
Ser Trp His Lys
Ser Trp His Gln
C25H32N8O7 (556.2393841999999)
Ser Trp Lys His
Ser Trp Gln His
C25H32N8O7 (556.2393841999999)
Thr His His Tyr
C25H32N8O7 (556.2393841999999)
Thr His Asn Trp
C25H32N8O7 (556.2393841999999)
Thr His Trp Asn
C25H32N8O7 (556.2393841999999)
Thr His Tyr His
C25H32N8O7 (556.2393841999999)
Thr Asn His Trp
C25H32N8O7 (556.2393841999999)
Thr Asn Trp His
C25H32N8O7 (556.2393841999999)
Thr Trp His Asn
C25H32N8O7 (556.2393841999999)
Thr Trp Asn His
C25H32N8O7 (556.2393841999999)
Thr Tyr His His
C25H32N8O7 (556.2393841999999)
Val Glu Phe Tyr
Val Glu Tyr Phe
Val Phe Glu Tyr
Val Phe Tyr Glu
Val Tyr Glu Phe
Val Tyr Phe Glu
Trp His Lys Ser
Trp His Asn Thr
C25H32N8O7 (556.2393841999999)
Trp His Gln Ser
C25H32N8O7 (556.2393841999999)
Trp His Ser Lys
Trp His Ser Gln
C25H32N8O7 (556.2393841999999)
Trp His Thr Asn
C25H32N8O7 (556.2393841999999)
Trp Lys His Ser
Trp Asn His Thr
C25H32N8O7 (556.2393841999999)
Trp Asn Thr His
C25H32N8O7 (556.2393841999999)
Trp Gln His Ser
C25H32N8O7 (556.2393841999999)
Trp Gln Ser His
C25H32N8O7 (556.2393841999999)
Trp Ser His Gln
C25H32N8O7 (556.2393841999999)
Trp Ser Gln His
C25H32N8O7 (556.2393841999999)
Trp Thr His Asn
C25H32N8O7 (556.2393841999999)
Trp Thr Asn His
C25H32N8O7 (556.2393841999999)
Tyr Asp Phe Ile
Tyr Asp Phe Leu
Tyr Asp Ile Phe
Tyr Asp Leu Phe
Tyr Asp Pro Tyr
Tyr Asp Tyr Pro
Tyr Glu Phe Val
Tyr Glu Val Phe
Tyr Phe Asp Ile
Tyr Phe Asp Leu
Tyr Phe Glu Val
Tyr Phe Ile Asp
Tyr Phe Leu Asp
Tyr Phe Met Pro
Tyr Phe Asn Asn
Tyr Phe Pro Met
Tyr Phe Val Glu
Tyr His His Thr
C25H32N8O7 (556.2393841999999)
Tyr His Thr His
C25H32N8O7 (556.2393841999999)
Tyr Ile Asp Phe
Tyr Ile Phe Asp
Tyr Ile Met Met
Tyr Leu Asp Phe
Tyr Leu Phe Asp
Tyr Leu Met Met
Tyr Met Phe Pro
Tyr Met Ile Met
Tyr Met Leu Met
Tyr Met Met Ile
Tyr Met Met Leu
Tyr Met Pro Phe
Tyr Asn Phe Asn
Tyr Asn Asn Phe
Tyr Pro Asp Tyr
Tyr Pro Phe Met
Tyr Pro Met Phe
Tyr Pro Tyr Asp
Tyr Thr His His
C25H32N8O7 (556.2393841999999)
Tyr Val Glu Phe
Tyr Val Phe Glu
Tyr Tyr Asp Pro
Tyr Tyr Pro Asp
Glaucarubolone 15-O-b-D-glucopyranoside
Dipiperamide C
C33H36N2O6 (556.2573236000001)
punaglandin 1
ST 30:9;O10
4-methoxyphenyl 2,4,6-tri-o-benzyl-beta-d-galactopyranoside
SB 224289 hydrochloride
C32H33ClN4O3 (556.2241058000001)
SB-224289 hydrochloride is a selective 5-HT1B receptor antagonist, with anxiolytic effect.
neratinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EH - Human epidermal growth factor receptor 2 (her2) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163760 - HER2-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159156 - HER2 Inhibitor
4-[(4-aminophenyl)methyl]aniline,1-[4-[[4-(2,5-dioxopyrrol-1-yl)phenyl]methyl]phenyl]pyrrole-2,5-dione
4-Methoxyphenyl 2,3,6-Tri-O-benzyl-beta-D-galactopyranoside
2-[3-(1,3-Dihydro-1,1,3-trimethyl-2H-benz[e]indol-2-ylidene)-1-propen-1-yl]-1,1,3-trimethyl-1H-benz[e]indolium perchlorate
N,N-[[5-[2-Amino-5-(2,2-dimethyl-1-oxopropyl)-4-thiazolyl]-2-furanyl]phosphinylidene]bis[2-methylalanine] diethyl ester
Isoprenaline
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D020011 - Protective Agents > D002316 - Cardiotonic Agents D002317 - Cardiovascular Agents
1H-1-Benzazepine-1-acetic acid, 3-(((1-((2R)-2-carboxy-4-(1-naphthalenyl)butyl)cyclopentyl)carbonyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (3S)-
C33H36N2O6 (556.2573236000001)
Pexmetinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
N-(3-hydroxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl)-N-methylbenzamide
N-[3-Fluoro-4-[(7-methoxyquinolin-4-yl)oxy]phenyl]-1-(2-hydroxy-2-methylpropyl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
Ananolignan L
A lignan with a dibenzocyclooctadiene skeleton isolated from Kadsura ananosma.
N-(2-Morpholin-4-YL-1-morpholin-4-ylmethyl-ethyl)-3-nitro-5-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-benzamide
[4-[4-[(E)-C-(4-bromophenyl)-N-ethoxycarbonimidoyl]piperidin-1-yl]-4-methylpiperidin-1-yl]-(2,4-dimethyl-1-oxidopyridin-1-ium-3-yl)methanone
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents D065100 - CCR5 Receptor Antagonists
2-[(4-Acetylamino-phenyl)-(2-benzotriazol-1-yl-acetyl)-amino]-2-(4-methoxy-phenyl)-N-(tetrahydro-furan-2-ylmethyl)-acetamide
[1-[(1,5-Dimethyl-3-oxo-2-phenylpyrazol-4-yl)amino]-1-oxopropan-2-yl] 2-naphthalen-1-ylquinoline-4-carboxylate
4-[(1R)-1-phenoxyethyl]-5-[5-[(1R)-1-phenoxyethyl]-3-(phenylmethyl)-4-triazolyl]-1-(phenylmethyl)triazole
2-fluoro-N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
(1R)-N-(2-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-2-(1-oxo-2-phenylethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
[(1R)-2-[(3,5-dimethoxyphenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-(3-pyridinyl)methanone
2-[[[(4R,5S)-8-(4-fluorophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl-methylamino]methyl]benzoic acid
2-[[[(4S,5R)-8-(4-fluorophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl-methylamino]methyl]benzoic acid
2-[[[(4R,5R)-8-(4-fluorophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl-methylamino]methyl]benzoic acid
2-[[[(4S,5S)-8-(4-fluorophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl-methylamino]methyl]benzoic acid
4-[3-[(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-(piperidine-1-carbonyl)-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]benzonitrile
1-[[(2R,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
2-[[[(4S,5R)-8-(4-fluorophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl-methylamino]methyl]benzoic acid
2-[[[(4R,5R)-8-(4-fluorophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl-methylamino]methyl]benzoic acid
2-[[[(4R,5S)-8-(4-fluorophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl-methylamino]methyl]benzoic acid
2-[[[(4S,5S)-8-(4-fluorophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl-methylamino]methyl]benzoic acid
3-[3-[(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-(piperidine-1-carbonyl)-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]benzonitrile
4-[3-[(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-[oxo(1-piperidinyl)methyl]-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]benzonitrile
2-fluoro-N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
3-[3-[(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-[oxo(1-piperidinyl)methyl]-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]benzonitrile
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-methyl-3-indolyl)acetamide
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-methyl-3-indolyl)acetamide
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-methyl-3-indolyl)acetamide
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-methyl-3-indolyl)acetamide
2-fluoro-N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
2-fluoro-N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
2-fluoro-N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
2-fluoro-N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
2-fluoro-N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
2-fluoro-N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
(1S)-N-(2-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-2-(1-oxo-2-phenylethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(2R)-3-hydroxy-2-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(octanoyloxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropanoic acid
[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (Z)-pentadec-9-enoate
[1-Propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] pentanoate
[1-Acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] hexanoate
[2-Butanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropyl] butanoate
(2R)-3-hydroxy-2-{[6-O-(6-O-octanoyl-alpha-D-glucopyranosyl)-alpha-D-glucopyranosyl]oxy}propanoic acid
1-(9Z-pentadecenoyl)-glycero-3-phospho-(1-myo-inositol)
3-vinylbacteriochlorophyllide d
A chlorophyllide obtained by hydrolysis of the terpenoid ester moiety of 3-vinylbacteriochlorophyll d.